Efficacy Comparison of Targeted Systemic Monotherapies Including Lebrikizumab for Moderate-to-Severe Atopic Dermatitis: a Network Meta-Analysis. J of Skin. 2024;8(1):s313. doi:10.25251/skin.8.supp.313